miRNA PC-5P-12969 expression levels in patients with acute ischemic stroke confirmed by intracranial imaging and a matched control group.

2019年，世界卫生组织将脑血管疾病视为全球第二大死亡原因，也是导致严重长期残疾的主要原因。因此，在短时间内诊断急性缺血性卒中（AIS）以避免严重后遗症至关重要。然而，在超急性期，急性脑成像（CT，MRI）检测AIS的灵敏度从57%到83%不等。生物标志物可能能够缩小这一诊断差距。到目前为止，还没有合适的生物标志物用于检测AIS。然而，新的miRNA PC-5 P-12969代表了非常有前途的生物标志物。在Vijayan等人的miRNA测序分析中，与健康对照相比，在AIS患者中检测了总共4656个miRNA。其中，4个miRNAs显示适合于进一步研究。特别是，新的miRNA PC-5 p-12969显示出显著的上调，并且一旦从组织释放到血液中似乎是稳定的，并且可以以高可靠性进行检测。该生物标志物可用于日常临床实践，而不会使患者暴露于任何风险。鉴于动脉高血压是卒中最重要的危险因素，并且现有证据表明高血压影响miRNA表达，因此将匹配对照与现有心血管危险因素（包括患有AIS的动脉高血压患者）进行比较非常重要。因此，本前瞻性实验研究的详细研究问题是“在颅内成像（CT/MRI）证实的急性缺血性卒中患者和匹配对照之间，入院时qRT-PCR测量的基于血液的miRNA PC-5 P-12969表达水平是否不同？“临床的主要目的是测量急性缺血性中风患者入院时及其亲属或合适的参与者（与风险特征匹配）血浆中的miRNA PC-5 P-12969表达水平。其他目标是：I）比较症状发作后90天± 14天观察到的功能结果（通过改良的兰金量表测量）与测量的miRNA PC-5 P-12969表达水平。II）比较以下组之间测量的miRNA PC-5 P-12969表达水平：症状发作后90 +/-14天复发性中风、无复发性中风。III）将入院时的miRNA PC-5 P-12969表达水平与其他变量（如检测到的中风的大小、从症状发作到血液采样的时间、肾功能、肌酐、收缩压）相关联。IIII）研究miRNA PC-5 P-12969表达水平的可能影响/相互作用变量。可能的影响变量：房颤、慢性心力衰竭、血脂异常、I型或II型糖尿病、高血压、酒精和尼古丁滥用

In 2019, the World Health Organization considered cerebrovascular disease the second leading cause of death worldwide and the leading cause of serious long-term disability. Therefore, it is of utmost importance to diagnose an acute ischemic stroke (AIS) in a short manner of time in order to avoid severe sequelae. However, the sensitivity for detecting AIS by acute brain imaging (CT, MRI) varies from 57% to 83% in the hyperacute phase. Biomarkers might be able to close this diagnostic gap. To date, no suitable biomarker for the detection of AIS is known. However, the novel miRNA PC-5P-12969 represents a very promising biomarker. In a miRNA sequencing analysis by Vijayan et al., a total of 4656 miRNAs were examined in AIS patients compared with healthy controls. Of those, 4 miRNAs showed to be suitable for further investigation. Especially, the novel miRNA PC-5p-12969 showed a pronounced up-regulation and seems to be stable once released to the blood from tissues and detection can be performed with high reliability. This biomarker can be used in daily clinical practice without exposing patients to any risks. Given that arterial hypertension constitutes the most important risk factor for stroke and existing evidence that hypertension impacts miRNA expression, it is important to compare matched controls with existing cardiovascular risk factors including arterial hypertension with patients suffering from AIS. Therefore, the elaborated research question of this prospective experimental study is "Are qRT-PCR measured blood-based miRNA PC-5P-12969 expression levels on admission different between in intracranial imaging-confirmed (CT/MRI) acute ischemic stroke patients and matched controls?" The primary objective of the clinical is to measure miRNA PC-5P-12969 expression levels in the plasma of patients with acute ischemic stroke on hospital admission and their relatives or suitable participants (matched for risk profile). Further aims are: I) to compare observed functional outcomes (measured by the modified Rankin Scale) 90 days +/- 14 days after symptom onset with measured expression levels of miRNA PC-5P-12969. II) To compare measured miRNA PC-5P-12969 expression levels between the following groups: recurrent stroke, no recurrent stroke 90 +/- 14 days after symptom onset. III) To correlate miRNA PC-5P-12969 expression levels on admission and other variables, such as size of detected stroke, time from symptom onset to blood sampling, renal function, creatinine, systolic blood pressure. IIII) To investigate possible influencing/interacting variables on the expression levels of miRNA PC-5P-12969. Possible influencing variables: atrial fibrillation, chronic heart failure, dyslipoproteinemia, diabetes mellitus type I or II, hypertension, alcohol and nicotine abuse